CoChat

Disruption of SUV39H1 -Mediated H3K9 Methylation Sustains CAR T-cell Function

Open access

Published version of a preprint

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Suboptimal functional persistence limits the efficacy of adoptive T-cell therapies. CD28-based chimeric antigen receptors (CAR) impart potent effector function to T cells but with a limited lifespan. We show here that the genetic disruption of SUV39H1, which encodes a histone-3, lysine-9 methyl-transferase, enhances the early expansion, long-term persistence, and overall antitumor efficacy of human CAR T cells in leukemia and prostate cancer models. Persisting SUV39H1-edited CAR T cells demonstrate improved expansion and tumor rejection upon multiple rechallenges. Transcriptional and genome accessibility profiling of repeatedly challenged CAR T cells shows improved expression and accessibility of memory transcription factors in SUV39H1-edited CAR T cells. SUV39H1 editing also reduces expression of inhibitory receptors and limits exhaustion in CAR T cells that have undergone multiple rechallenges. Our findings thus demonstrate the potential of epigenetic programming of CAR T cells to balance their function and persistence for improved adoptive cell therapies. Significance: T cells engineered with CD28-based CARs possess robust effector function and antigen sensitivity but are hampered by limited persistence, which may result in tumor relapse. We report an epigenetic strategy involving disruption of the SUV39H1-mediated histone-silencing program that promotes the functional persistence of CD28-based CAR T cells. See related article by López-Cobo et al., p. 120. This article is featured in Selected Articles from This Issue, p. 5

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-22-1319

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 70 · Cited by 95

Metadata

Authors
Jain, N., Zhao, Z., Koche, R. P., Antelope, C., Gozlan, Y., Montalbano, A., Brocks, D., Lopez, M., Dobrin, A., Shi, Y., Gunset, G., Giavridis, T., & Sadelain, M.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • Immunai (United States) (US)
  • 5Mnemo Therapeutics, New York, New York.
Corresponding author
Sadelain, Michel
Venue
Cancer Discovery
Published
2023-10-31
Volume
14
Issue
1
Pages
142-157
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W4388464258
Cited by
95
References
70
Citations by year
2026: 28 · 2025: 39 · 2024: 27 · 2023: 1
FWCI
11.54
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Cancer Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion, cc-by)
Funders
National Cancer Institute (P30 CA008748)
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
SUV39H1, H3K9 methylation, chimeric antigen receptor T cells, T cell persistence, epigenome editing, histone methyltransferase, T cell exhaustion, inhibitory receptors, genome accessibility, leukemia, prostate cancer, adoptive immunotherapy, tumor recurrence
MeSH terms
Receptors, Chimeric Antigen, Histones, Humans, Leukemia, Male, Methylation, Methyltransferases, Receptors, Antigen, T-Cell, Repressor Proteins, T-Lymphocytes, Immunotherapy, Adoptive, CD28 Antigens, Xenograft Model Antitumor Assays

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Disruption of SUV39H1 -Mediated H3K9 Methylation Sustains CAR T-cell Function. https://app.cochat.ai/papers/10.1158/2159-8290.cd-22-1319
The paper
Jain, N., Zhao, Z., Koche, R. P., Antelope, C., Gozlan, Y., Montalbano, A., Brocks, D., Lopez, M., Dobrin, A., Shi, Y., Gunset, G., Giavridis, T., & Sadelain, M. (2024). Disruption of SUV39H1 -Mediated H3K9 Methylation Sustains CAR T-cell Function. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-22-1319

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.